Image source: Getty Images.
What: Shares of clinical-stage oncology company Geron Corporation (NASDAQ: GERN) fell by over 10% last month, according to data from S&P Global Market Intelligence. The biotech’s stock price took a hit as a result of the market-wide pullback stemming from Britain’s decision to leave the European Union.